Melanie D. Whittington

Dec 2, 2024 | bizjournals.com | Melanie D. Whittington

The FDA approval represented the first significant innovation in the approach used to treat schizophrenia in decades. A Leerink Center for Pharmacoeconomics (CPE) Exclusive suggests the price for Cobenfy™ is less than the quantifiable societal benefit it may provide even under conservative assumptions. The U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) on Sept. 26.

May 6, 2024 | statnews.com | Jason Shafrin |Louis P. Garrison |Melanie D. Whittington

The changing landscape of drug pricing policy in the U.S. has implications for the global pace and direction of innovation. Drug policy changes are being influenced by perceptions of the value of novel medicines relative to their budgetary impacts, with some believing that many medicines may not be worth their cost, creating an important role for health technology assessments (HTA).

Oct 18, 2023 | healthaffairs.org | Melanie D. Whittington |Peter J. Neumann |Joshua Cohen |Jonathan D. Campbell

This commentary argues that practitioners of cost-effectiveness analyses should incorporate dynamic drug pricing into formal cost-effectiveness analyses (CEAs). For reasons we discuss, doing so will more accurately reflect drug costs over time.